Wall Street analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.30). Iovance Biotherapeutics posted earnings of ($0.20) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 60%. The firm is expected to announce its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.35) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.23). For the next financial year, analysts forecast that the firm will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.49) to ($1.08). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Iovance Biotherapeutics.
A number of research firms have recently issued reports on IOVA. HC Wainwright set a $22.00 price objective on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Tuesday, October 17th. Jefferies Group increased their price objective on shares of Iovance Biotherapeutics to $31.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Oppenheimer set a $13.00 price objective on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. Finally, ValuEngine upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $18.75.
A number of institutional investors and hedge funds have recently made changes to their positions in IOVA. Legal & General Group Plc acquired a new stake in Iovance Biotherapeutics in the second quarter valued at approximately $103,000. Parametric Portfolio Associates LLC acquired a new stake in Iovance Biotherapeutics in the second quarter valued at approximately $125,000. Dynamic Technology Lab Private Ltd acquired a new stake in Iovance Biotherapeutics in the third quarter valued at approximately $133,000. Edge Wealth Management LLC acquired a new stake in Iovance Biotherapeutics in the third quarter valued at approximately $150,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Iovance Biotherapeutics in the fourth quarter worth $154,000. Institutional investors own 64.53% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/brokerages-anticipate-iovance-biotherapeutics-inc-iova-to-announce-0-32-eps.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.